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ABSTRACT 
The present research work describes a simple, accurate, precise, effective, Stability indicating RP-HPLC method for simultaneous estimation of 
Sofosbuvir and Ledipasvir in their tablet dosage form. A reverse phase high performance chromatographic method wa s developed for 
simultaneous estimation of Sofosbuvir and Ledipasvir their combined dosage. The separation was achieved by Inertsil ODS C18 column 
(150X4.6mm, 5µm) column, and ACN: 0.1% TFA in the proportion of 30:70 %v/v as mobile phase, at a flow rate of 1 ml/min. Detection was 
carried out at 245 nm.  For RP-HPLC method results of the validation indicate that the method was linear in the range of 100-600μg/ml for 
Sofosbuvir and 22.5-135μg/ml for Ledipasvir.  The % recoveries for Sofosbuvir and Ledipasvir obtained in the accuracy study were 99.92-
100.31% and 99.84-100.55% respectively. The LOD for Sofosbuvir and Ledipasvir were found to be 0.395μg/ml and 0.132μg/ml respectively. 
LOQ for Sofosbuvir and Ledipasvir were found to be 1.197μg/ml and 0.401μg/ml respectively. Force degradation study also done and method 
is stability indicating. Developed methods were found to be accurate, precise, rapid and stability indicating for simultaneous estimation of 
Sofosbuvir and Ledipasvir. 
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INTRODUCTION 
1.1 SOFOSBUVIR 
propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-
1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-
phenoxyphosphoryl]amino]propanoate.[1] It is indicated for 
the treatment of chronic HCV genotypes 1, 4, 5, and 6 in 
adults and also indicated for the treatment of chronic HCV in 
patients co-infected with HIV. [2] Slightly soluble in water pH 
1.2-7.7, freely soluble in ethanol and acetone, soluble in 2-
propanol and insoluble in heptanes.[3]      
Mol. formula: C22H29FN3O9P     Mol. weight: 529.4525242 
gm/mol . 
Structure: 
 
Figure 1: Chemical structure of Sofosbuvir 
Mechanism of action: Sofosbuvir is a direct-acting antiviral 
agent against the hepatitis C virus. The HCV polymerase 
NS5B protein is an RNA-dependent RNA polymerase (RdRp). 
It is the essential initiating and catalytic subunit of this 
replication complex and is critical for the viral replication 
cycle. There is no human homolog for HCV NS5B RdRp. 
Sofosbuvir is a monophosphorylated pyrimidine nucleotide 
prodrug that undergoes intracellular metabolism to form the 
pharmacologically active uridine analog triphosphate (GS-
461203). GS-461203 competes with natural nucleotides for 
incorporation (by HCV NS5B) into the nascent RNA strand 
during replication of the viral genome.GS-461203 differs 
from endogenous pyrimidine nucleotides in that it has been 
modified at the 2' position with the addition of a methyl and 
a fluoro functional group. Incorporation of GS-461203 into 
nascent RNA strongly reduces the efficiency of further RNA 
elongation by RdRp, resulting in premature termination of 
RNA synthesis. The stopping of viral replication leads to a 
rapid decline of HCV viral load and clearing of HCV levels in 
the body.[4,5] 
1.2. LEDIPASVIR 
The chemical name is methyl [(2S)-1-{(6S)-6-[4-(9,9-
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difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-
azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-
fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-
methyl-1-oxobutan-2-yl]carbamate [6]. Ledipasvir is 
practically insoluble <0.1 mg/ml across the pH range of 3.0-
7.5 and is slightly soluble below pH 2.3 1.1 mg/ml. The 
partition coefficient  for Ledipasvir is 3.8 and the pKa1 is 4.0 
and pKa2 is 5.0.[7] 
Molecular formula: C49H54F2N8O6   
Molecular weight: 888.999866  gm/mole. 
Structure:  
 
Figure 2: Chemical structure of Ledipasvir 
 Mechanism of action: 
Ledipasvir inhibits an important viral 
phosphoprotein, NS5A, which is involved in viral replication, 
assembly, and secretion. Ledipasvir is an inhibitor of the 
Hepatitis C Virus (HCV) NS5A protein required for viral RNA 
replication and assembly of HCV virions. Although its exact 
mechanism of action is unknown, it is postulated to prevent 
hyperphosphorylation of NS5A which is required for viral 
production. It is effective against genotypes 1a, 1b, 4a, and 
5a and with a lesser activity against genotypes 2a and 3a of 
HCV [8,9] 
According to the best of our knowledge, only four HPLC 
methods[10-13] have been published, during the preparation 
of the present work for publishing. The present study aimed 
to develop a simple, sensitive, short retention time and 
accurate RP-HPLC method for the simultaneous 
determination of both sofosbuvir and ledipasvir together in 
pure and tablet dosage forms with high sensitivity, 
selectivity that can be used for the routine analysis of 
production samples.   
2. MATERIAL AND METHOD 
 2.1. Instruments and Apparatus : 
 Ultrasonic Cleaner-5510  
 Glass wares – volumetric flask (10, 50 and 100 ml), 
pipettes beaker (500 ml), measuring cylinder(25, 50, 
100 ml) (Borosil )  
 What man filter paper no.41  
 Thermo separation HPLC (Assemble), UV-200 detector 
(single wavelength), Rheodyne injector (20 µl). 
 0.45 µm Nylon 66 (Milipore, India)  
 Analytical Balance (Swisser) 
All instruments and glass wares were calibrated. 
 
2.2. Preparation of Solutions 
 Preparation of the Buffer solution 
Diluted 1.0 ml of Trifluoro acetic acid in 1000ml of purified 
water and mixed. 
Filter the resultant solution through 0.45μm Nylon 
membrane filter. 
 Preparation of the Mobile phase  
Prepared a filtered and degassed mixture of buffer solution 
and acetonitrile in the ratio of (70:30 %v/v). 
2.3. Preparation of Standard Solutions 
 Preparation of Standard Solution of Sofosbuvir 
Accurately weighed quantity of Sofosbuvir 200.00 mg was 
transferred into   100 ml volumetric flask, sonicated to 
dissolve and diluted up to mark with diluent to give a stock 
solution 2000μg/ml. An aliquot 5.0 ml of the solution was 
transferred to 50 ml volumetric flask and diluted to the mark 
with diluent to obtain a working standard solution 
200μg/ml of Sofosbuvir. 
 Preparation of Standard Solution of Ledipasvir 
Accurately weighed quantity of Ledipasvir 45.00 mg was 
transferred into 100 ml volumetric flask, sonicated to 
dissolve and diluted up to mark with diluent to give a stock 
solution 450μg/ml. An aliquot 5.0 ml of the solution was 
transferred to a 50 ml volumetric flask and diluted to the 
mark with diluent to obtain a working standard solution 
45μg/ml of Ledipasvir. 
 Preparation of Combined Standard Solution of 
Sofosbuvir and Ledipasvir: 
Accurately weighed Sofosbuvir 200.00 mg and Ledipasvir 
45.00 mg were transferred into 100 ml volumetric flask, 
sonicated to dissolve and diluted up to mark with diluent to 
give a stock solution 2000μg/ml of Sofosbuvir and 450μg/ml 
Ledipasvir. Designate it as a combine stock solution 
Stock solution 5.0 ml was transferred to 50 ml volumetric 
flask and diluted up to mark with diluent to obtain working 
standard solution 200μg/ml of Sofosbuvir and 45μg/ml 
Ledipasvir.  
 Preparation of Sample Solution of Sofosbuvir and 
Ledipasvir 
Twenty tablets were weighed and finely powdered. 
Powdered equivalent to 400 mg Sofosbuvir and 90 mg 
Ledipasvir was accurately weighed and transferred to 200 
ml volumetric flask, and 140 ml of diluent was added and 
sonicated for  20 min finally  volume was made up to the 
mark with diluent. The solution was filtered through 
whatmann filter paper (0.45µ). From this solution 5.0 ml 
was transferred to 50 ml volumetric flask and volume was 
made up to the mark with diluent to give a solution 
containing 200μg/ml Sofosbuvir and 45μg/ml Ledipasvir. 
 2.4. Selection of Wavelength for Estimation 
Standard solution of Sofosbuvir 40μg/ml and Ledipasvir 
9.0μg/ml were prepared using their working standard 
solution using diluent as a solvent. Each solution was 
scanned between 200-400 nm using diluent as a blank. The 
point at which both drug shows absorbance was selected as 
wavelength for estimation (245nm). 
 
Mankar et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):500-509 
ISSN: 2250-1177                                                                                   [502]                                                                                     CODEN (USA): JDDTAO 
 
Figure 3: Spectra of standard Sofosbuvir and Ledipasvir for wavelength selection 
 
Table 1: Optimized chromatographic condition 
Parameters Condition 
Stationary phase 
Inertsil ODS C18 column (150mm X 4.6 mm, 5 µm 
particle size)s 
Mobile Phase 0.1% TFA : Acetonitrile (70:30%v/v) 
Pump mode Isocratic 
Flow rate (ml/min) 1.0 
Run time (min) 7.0 
Volume of Injection (µl) 20 
Detection wavelength 245 
Retention time (min) 
Sofosbuvir : 2.39 
Ledipasvir : 5.51 
 
Table 2: System suitability parameters for final optimized chromatographic conditions 
Parameters 
Data obtained 
Sofosbuvir Ledipasvir 
Retention time (Rt) 2.39min 5.51 min 
Resolution 7.22 
Theoretical plates (N) 4025 8977 
Tailing factor (Tf) 1.05 1.11 
 
So, from all the above explained parameters, it was concluded that that the most efficient resolution and peak symmetry for 
Sofosbuvir and Ledipasvir were achieved with the above chromatographic conditions and with a mobile phase composed of 
0.1%TFA :Acetonitrile (70 : 30 %v/v)  
 
Figure 4: Chromatogram of standard showing separated peaks of Sofosbuvir and  Ledipasvir 
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3. Method Validation 
The described method has been validated for linerity, 
accuracy, limit of detection, precision, and robustness, as per 
ICH guidelines.[14] 
3.1. Linearity and Range: 
Linear relation was obtained between mean peak area and 
concentration of the drug in the range of 100-600 μg/ml for 
Sofosbuvir and 22.5-135 μg/ml for Ledipasvir. The data of 
the peak areas obtained with the respective concentration in 
μg/ml are shown in Table 3 and 5 for Sofosbuvir and 
Ledipasvir respectively. The linearity curves for Sofosbuvir 
and Ledipasvir are shown in Fig.5 and 6 respectively. 
Table 3: Data of peak areas of Sofosbuvir(100-
600μg/ml) 
Sr. 
No. 
Concentration 
(μg/ml) 
Peak area of 
Sofosbuvir 
1 100 6018619 
2 200 12053329 
3 300 18074368 
4 400 24115257 
5 500 30130479 
6 600 36151273 
 
 
Fig. 5: Calibration curve for Sofosbuvir 
Table 4: Data showing regression characteristics of Sofosbuvir 
Regression equation Y = 60267.3169x – 3006.7333 
Regression co-efficient 1.0000 
 
Table 5: Data of peak areas of Ledipasvir (22.5-135 μg/ml) 
 Sr. No. 
Concentration 
(μg/ml) 
Peak area of Ledipasvir 
1 22.5 806846 
2 45 1618653 
3 67.5 2427643 
4 90 3237175 
5 112.5 4043608 
6 135 4855008 
 
 
Fig. 6 : Calibration curve for Ledipasvir 
y = 35969x - 1031.9 
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Table 6: Data showing regression characteristics of Ledipasvir 
Regression equation Y = 35968.52x-1031.8667 
Regression co-efficient 1.0000 
 
3.2. Accuracy  
Accuracy refers to closeness of the test results obtained by the method to the true value. Accuracy was performed by the 
standard addition methods. To a fixed amount of the pre-analysed mixture add a 50%, 100% and 150% of the standard solution 
and % recovery was calculated.  The results are shown in Table 7 
Table 7: Recovery data for Sofosbuvir 
Amount of 
Sofosbuvir 
Present 
(µg/ml) 
Amount of Std 
Sofosbuvir 
Added (µg/ml) 
Total Amount 
of Sofosbuvir  
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
% Recovery 
 
200 300 500 
499.830 
99.92  501.982 
496.986 
200 200 400 
401.139 
99.72  396.993 
398.532 
200 100 300 
300.381 
100.31 300.357 
302.039 
 
Table 8: Recovery data for Ledipasvir 
Amount of 
Ledipasvir Present 
(µg/ml) 
Amount of Std 
Ledipasvir Added 
(µg/ml) 
Total Amount 
of Ledipasvir  
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
% Recovery 
 
45 67.5 112.5 
112.575 
100.45      113.023 
113.423 
45 45 90 
90.652 
99.84        89.607 
89.307 
45 22.5 67.5 
67.035 
100.55     68.129 
68.453 
 
3.3. Precision 
3.3.1. Repeatability  
It was performed by 100% test concentration level and % RSD was calculated. The data for repeatability for combined solution 
of Sofosbuvir and Ledipasvir is presented in Table 9 
Table 9: Repeatability of Sofosbuvir and Ledipasvir 
Sr. No. Sofosbuvir (200 μg/ml) Ledipasvir (45μg/ml). 
1 12363864 1532054 
2 12264518 1528040 
3 12288474 1530889 
4 12289526 1530928 
5 12303266 1532196 
6 12245790 1552151 
Mean 12292573 1534376 
SD 40493.37 8835.02 
% RSD 0.33 0.58 
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3.3.2. Interday and Intraday Precision of Sofosbuvir: 
The data for Intraday and Interday precision for Sofosbuvir 
are presented in Table 10 for Intraday Sample solutions 
containing 200µg/ml of Sofosbuvir and 45µg/ml Ledipasvir 
were prepared six times and measured on the same day 
and % RSD was calculated. For Interday Sample solutions 
containing 200µg/ml of Sofosbuvir and 45µg/ml Ledipasvir 
were prepared six times and measured on the different days 
and % RSD was calculated. 
 
Table 10: Intraday and Interday precision data for Sofosbuvir 
Concentration 
(μg/ml) 
Intraday Interday 
Mean % Estimation ± 
SD 
% RSD 
Mean % Estimation ± 
SD 
% RSD 
200 100.10 ± 0.5462 0.55 100.24 ± 0.7162 0.71 
 
3.3.3. Intraday and Interday Precision of Ledipasvir : 
The data for Intraday and Interday precision for Ledipasvir 
are presented in Table: 10 The % RSD for Intraday precision 
was found to be 0.53 for Ledipasvir. The % RSD for Interday 
precision was found to be 0.67 for Ledipasvir. 
 
Table 11: Intraday and Interday precision data of Ledipasvir 
Concentration 
(μg/ml) 
Intraday  Interday 
 Mean % Estimation ± SD % RSD Mean % Estimation  ± SD % RSD 
45 100.05 ± 0.5281 0.53 100.03 ± 0.6682 0.67 
 
3.4. Limit of Detection (LOD) and Limit of Quantification (LOQ) 
Table 12: Limit of detection 
Sofosbuvir Ledipasvir 
LOD = 3.3 x (SD/Slope) 
LOD = 3.3 x (7214/60267.3169) 
LOD = 0.395 μg/ml 
LOD = 3.3 x (SD/Slope) 
LOD = 3.3 x (1443/35968.5168) 
LOD = 0.132 μg/ml 
 
Table 13:  Limit of Quantification 
Sofosbuvir Ledipasvir 
LOQ = 10 x (SD/Slope) 
LOQ = 10 x (7214/60267.3169) 
LOQ = 1.197 μg/ml 
LOQ = 10 x (SD/Slope) 
LOQ = 10 x (1443/35968.5168) 
LOQ = 0.401 μg/ml 
 
3.5. Specificity 
The specificity was determined by the comparison of the chromatograms of: 
 Blank (mobile phase) (Fig 7) 
 Standard sample solutions of Sofosbuvir and Ledipasvir(Fig.8 and 9 for Sofosbuvir and Ledipasvir respectively), 
 Sample solution of Sofosbuvir and Ledipasvir (Fig. 10). 
 
Fig.7: Chromatogram of Blank (mobile phase) 
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Fig. 8: Chromatogram of standard Sofosbuvir 
 
Fig. 9: Chromatogram of standard Ledipasvir 
 
Fig. 10: Chromatogram of sample solution containing Sofosbuvir(200μg/ml) and Ledipasvir (45μg/ml) 
 
3.6.   Robustness 
Robustness study was performed in following altered chromatographic   condition: 
Variation in the flow rate (± 0.2 mL/min) 
Variation in mobile phase composition (± 2% ) 
         
Table 14: Robustness data for ± 0.2 mL/min variation in Flow rate 
Flow 
rate 
Peak area Mean±SD % RSD 
SOFOS LEDI SOF LED SOF LED 
0.8 
mL/min 
14313927 1757607 14350196 ± 
51292.1117 
1757224 ± 
540.9367 
0.36 0.03 
14386465 1756842 
1.2 
mL/min 
11094624 1380696 11096462 ± 
2599.3245 
 
1380890 ± 
275.0645 
 
0.02 0.02 
11098300 1381085 
 
Table 15: Robustness data for ± 2% variation in mobile phase 
Mobile 
phase 
Peak area Mean±SD % RSD 
SOFOS LEDI SOF LED SOF LED 
72:28 
12441394 1540933 12450838± 
13355.1258 
1542977 ± 
2889.9454 
0.11 0.19 
12460281 1545020 
68:32 
12371514 1547725 12371612± 
137.8858 
1547848 ± 
173.9483 
0.00 0.01 
12371709 1547971 
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4. Assay Formulation analysis 
Table 16: Estimation of Sofosbuvir and Ledipasvir in their Pharmaceutical Dosage Form (Tablet) 
Labelled 
Value (mg) 
Amt of 
Sofosbuvir found 
(mg) 
% Assay 
Labelled 
Value (mg) 
Amt of 
Ledipasvir found 
(mg) 
% Assay 
400 
402.16 100.54 
90 
90.20 100.23 
398.92 99.73 89.66 99.62 
402.05 100.51 90.00 100.01 
403.38 100.84 90.26 100.29 
401.36 100.34 90.41 100.46 
402.93 100.73 90.00 100.00 
Mean 401.80 100.45 Mean 90.09 100.10 
SD 1.5791 0.3948 SD 0.2625 0.2917 
% RSD 0.39 0.39 % RSD 0.29 0.29 
 
5. Force degradation studies 
5.1. Preparation of sample stock solution  
Accurately weighed Sofosbuvir (200.00 mg) and Ledipasvir 
(45.00 mg) were transferred into 100 ml volumetric flask, 
sonicated to dissolve and diluted up to mark with diluent to 
give a stock solution (2000μg/ml) of Sofosbuvir and 
(450μg/ml) Ledipasvir. Designate it as a combine stock 
solution. Stock solution (5.0 ml) was transferred to 50 ml 
volumetric flask and diluted up to mark with diluent to 
obtain working standard solution (200μg/ml) of Sofosbuvir 
and (45μg/ml) Ledipasvir. 
5.2. Acid degradation study (5NHCL) 
From the test stock solution 1ml was taken in 10 ml 
volumetric flask, add 1ml of 5N HCL and heated at 60˚ for 30 
min on a water bath. The flask was removed from the water 
bath and allows to cool at room temperature. Add 1ml of 5N 
NaoH to neutralize the solution and diluted to volume with 
diluents and mixed. 10µl solution were injected in to the 
system and the chromatograms were recorded to assess the 
stability of sample. 
5.3. Alkali degradation studies (5N NaoH) 
From the test stock solution 1ml was taken in 10ml 
volumetric flask, add 1ml of 5N NaoH and heated at 70˚c for 
1h on a water bath. The flask was removed from the water 
bath and allowed to cool at room temperature. Add 1ml of 5 
N HCL to neutralize the solution and diluted to volume with 
diluents and mixed.10µl  solution were injected in to the 
systeam and chromatograms were recorded to asses the 
stability of sample. 
5.4. peroxide (Oxidation) degradation studies (30%v/v 
of H2O2) 
From the test stock solution 1ml Was taken in 10ml 
volumetric flask add 1ml of 30% H2O2 and heated at 70˚ c 
for 1hour on a water bath. The flask was removed from the 
water bath and allowed to cool at room temperature and 
diluted to volume with diluents and mixed. 10µl solutions 
were injected in to the systeam and the chromatograms 
were recorded to acess the stability of sample. 
5.5. Thermal degradation studies (105˚c/ 48hr) 
For the thermal degradation 200mg Sofosbuvir and 45mg 
lLedipasvir drug samples were weighed accurately and 
transfer to petridish heat the sample in oven for 48hr at  
105˚c and transfer the sample into a 100ml volumetric flask 
dissolve and dilute to volume with diluents. Filter the 
solution using 0.45µ Nyllon filter. Transfer 5ml of above 
stock solution to 50ml volumetric flask and make up the 
volume with diluents to get the concentration of (200μg/ml) 
of Sofosbuvir and (45μg/ml) Ledipasvir. 10 µl solutions was 
injected into the system and the chromatogram recorded to 
access the stability of sample. 
5.6. Photolytic degradation (2600lux for 24hr) 
For the thermal degradation 200mg Sofosbuvir and 45mg 
lLedipasvir drug samples were weighed accurately and 
transfer to petridish. The sample was exposed to UV light in 
a photolytic chamber at 1.2 millon lux hours for 24h and 
transfer the sample into a 100ml volumetric flask dissolve 
and dilute to volume with diluents. Filter the solution using 
0.45µ Nyllon filter. Transfer 5ml of above stock solution to 
50ml volumetric flask and make up the volume with diluents 
to get the concentration of (200μg/ml) of Sofosbuvir and 
(45μg/ml) Ledipasvir. . 10µl solutions was injected into the 
systeam and the chromatogram recorded to access the 
stability of sample. 
6. RESULT AND DISCUSSION 
6.1.  Optimized chromatographic conditions 
The optimized chromatographic conditions fig3. The best 
peak shape and maximum separation was achieved with 
mobile phase ACN : 0.1% TFA in the proportion of 
30:70 %v/v, peak symmetry and reproducibility obtained 
on  inetsil ODS C18 column (150X4.6mm, 5µm), optimum 
Wave length To detecting analyte was found to be 245 nm , 
a flow rate of 1ml/min yield optimum separation and peak 
symmetry. Chromatogram of Sofosbuvir and Ledipasvir fig  4 
and optimized chromatographic condition is shown in table 
1. 
6.2. Linearity 
Linear relation was obtained between mean peak area and 
concentration of the drug in the range of 100-600 μg/ml for 
Sofosbuvir and 22.5-135 μg/ml for Ledipasvir. Shown in the 
fig 5 and 6. 
6.3. Accuracy 
The percentage recovery for Sofosbuvir were 99.72-
100.31% and for Ledipasvir 99.84-100.55%.shown in the 
Table 6 and 7. 
6.4. Precision 
6.4.1 Repeatability 
The data for repeatability for combined solution of 
Sofosbuvir and Ledipasvir is presented in Table: 8 and % 
RSD was found to be 0.33 for Sofosbuvir and 0.58for 
Ledipasvir.  
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6.4.2  Intraday and interday precision 
The data for Intraday and Interday precision for Sofosbuvir 
are presented in Table: 9. The % RSD for Intraday precision 
was found to be 0.55 for Sofosbuvir. The % RSD for Interday 
precision was found to be 0.71 for Sofosbuvir. 
The data for Intraday and Interday precision for Ledipasvir 
are presented in Table: 10. The % RSD for Intraday precision 
was found to be 0.53 for Ledipasvir. The % RSD for Interday 
precision was found to be 0.67 for Ledipasvir. 
6.5. LOD and LOQ 
The LOD for Sofosbuvir and Ledipasvir were found to be 
0.395μg/ml and 0.132μg/ml respectively, shown in table no 
11. 
LOQ for Sofosbuvir and Ledipasvir were found to be 
1.197μg/ml and 0.401μg/ml respectively, shown in table 12. 
6.6. Specificity  
The specificity of the method was evaluated with regard to 
interferance due to presence of any othe excipient. The figure 
show that the selected drugs were clearly separated. Fig  7 and 
10    show that the chromatogram of blank , standard. solution. 
There were no interfering peak at retention time of Sofosbuvir 
and Ledipasvir. 
6.7.Robustness 
Result of the robustness Table 13 & 14. The elution order and 
resolution for all components were not significantly affected. 
RSD of peak area were found to be well within the limit of 2.0%. 
6.8. Degradation study 
All the stability results were shown in table 16 and fig 11 (a-e) 
Table 17: stability results 
Stress 
Condition  
Sofosbuvir Ledipasvir 
% Degradation % Degradation 
Acid 0.44 1.18 
Basic 0.02 0.05 
Oxidizing 0.41 1.73 
Thermal 0.04 0.05 
Photolysis 0.01 0.07 
 
 
[a]                                                                                      [b] 
 
[c]                                                                                       [d] 
 
[e] 
Fig 11: (a) Acid degradation (b) alkali degradation (c) peroxide degradation (d) thermal degradation (e) photodegradation 
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7. CONCLUSION 
A simple, fast, accurate and precise stability- indicating HPLC 
analytical method has been developed and validated for the 
Quantitative analysis of Sofosbuvir and Ledipasvir in 
combined tablet dosage forms. The result of stress testing 
undertake according to the ICH guidelines reveal that the 
method is specific and stability indicating. The proposed 
method has the ability to separate these drugs from their 
degradation products in tablet dosage forms and hence can 
be applied to the analysis of routine quality control samples 
obtained from stability studies. 
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